Thomas Graillon completed an MD specialisation in neurosurgery at Aix Marseille University in 2012, a PhD in neurosciences at Aix Marseille University in 2016, and an HdR in neurosciences at Aix Marseille University in 2020. He is an expert in meningiomas and the leader of two clinical trials, CEVOREM (octreotide and everolimus) and ALTREM (alpelisib and trametiniv), in aggressive meningiomas.